Breast cancer treatment for its progression in 75% of cases

An international team of scientists led by Spain recently presented data from a breast cancer treatment which is a wave of hope in the gray times in which we live. It is Trastuzumab deruxtecana combination of a targeted drug and a chemotherapy drug. The results are so good that the progression-free survival rate has increased from 34.1% with a previous combination with 75.8% with that.

So far, this much lower percentage has been achieved with a mixture of the same targeted drug, but a different chemotherapy: emtansine. It was considered a good choice in the existing possibilities against cancer HER2 positiveone of metastatic breast tumors more aggressive. But this new combination, tested in the DESTINY Breast03 clinical trial and presented in a study in The New England Journal of MedicineIt seems much more efficient.

Logically, it will be necessary to follow these patients with breast cancer longer, to make sure everything is going well. However, the results we have at this time give us plenty of reason to be optimistic. And it never hurts to stick with it.


Tens of thousands of breast cancer cases each year

According to data from the Spanish Society of Medical Oncology, in 2020 they were diagnosed in Spain 32,953 new cases of breast cancer. According to the Observatory of the Spanish Association against Cancer, in 2021 there were 34,333. 1 in 8 women in our country will have breast cancer throughout her life.

Fortunately, it is one of the tumors with the best prognosis if diagnosed early. In fact, the survival at stage I it is over 98%, while at stage IV it drops to 24%. This is why screening is so important. mammograms. However, the most aggressive tumors, such as HER2 positiveare much more serious.